Brandaris Therapeutics

Brandaris Therapeutics is a translational-stage biotech pioneering a new frontier in neuroscience and the treatment of neuropsychiatric disorders. Taking a disruptive approach to classical receptor pharmacology, the company develops targeted therapies with a differentiated mechanism of action, with molecules anticipated to deliver marked, rapid-onset and durable efficacy with favourable side-effect profiles. Brandaris addresses the gap left by current treatments—where millions of patients experience inadequate relief—with first-in-class and best-in-class drug candidates backed by preclinical and translational data for conditions such as depression and anxiety disorders.